Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 11fludarabine 8Dexamethasone 7pomalidomide 6pembrolizumab 6Rituximab 5obinutuzumab 4glofitamab 4daratumumab 4Immunotherapy, Adoptive 4Gemcitabine 4Bortezomib 4venetoclax 3selinexor 3fludarabine phosphate 3cemiplimab 3Temozolomide 3Nivolumab 3Melphalan 3Injections 3Etoposide 3zanubrutinib 2tocilizumab 2pirtobrutinib 2blinatumomab 2abemaciclib 2Sirolimus 2Oxaliplatin 2Mesna 2Lisaftoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × 18-O-demethylcervinomycin A2 × 30 days × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡